Ironbridge Capital Management Lp Lowers stake in Eli Lilly and Co (LLY)

Eli Lilly and Co (LLY) : Ironbridge Capital Management Lp reduced its stake in Eli Lilly and Co by 0.02% during the most recent quarter end. The investment management company now holds a total of 456,880 shares of Eli Lilly and Co which is valued at $36,650,914 after selling 90 shares in Eli Lilly and Co , the firm said in a disclosure report filed with the SEC on Aug 10, 2016.Eli Lilly and Co makes up approximately 1.54% of Ironbridge Capital Management Lp’s portfolio.

Other Hedge Funds, Including , Edmond De Rothschild Holding S.a. reduced its stake in LLY by selling 190 shares or 2.96% in the most recent quarter. The Hedge Fund company now holds 6,220 shares of LLY which is valued at $498,968. Eli Lilly and Co makes up approx 0.02% of Edmond De Rothschild Holding S.a.’s portfolio.Columbus Circle Investors reduced its stake in LLY by selling 299,929 shares or 19.46% in the most recent quarter. The Hedge Fund company now holds 1,241,679 shares of LLY which is valued at $102,711,687. Eli Lilly and Co makes up approx 0.98% of Columbus Circle Investors’s portfolio.Mitsubishi Ufj Kokusai Asset Management Ltd. boosted its stake in LLY in the latest quarter, The investment management firm added 30,982 additional shares and now holds a total of 199,839 shares of Eli Lilly and Co which is valued at $16,530,682. Eli Lilly and Co makes up approx 0.42% of Mitsubishi Ufj Kokusai Asset Management Ltd.’s portfolio.Eastern Bank reduced its stake in LLY by selling 146 shares or 1.19% in the most recent quarter. The Hedge Fund company now holds 12,154 shares of LLY which is valued at $971,712. Eli Lilly and Co makes up approx 0.08% of Eastern Bank’s portfolio.

Eli Lilly and Co closed down -0.72 points or -0.90% at $79.06 with 37,46,012 shares getting traded on Friday. Post opening the session at $79.55, the shares hit an intraday low of $78.78 and an intraday high of $79.79 and the price fluctuated in this range throughout the day.Shares ended Friday session in Red.

On the company’s financial health, Eli Lilly and Co reported $0.86 EPS for the quarter, beating the analyst consensus estimate by $ 0.01 according to the earnings call on Jul 26, 2016. Analyst had a consensus of $0.85. The company had revenue of $5404.80 million for the quarter, compared to analysts expectations of $5157.09 million. The company’s revenue was up 8.6% compared to the same quarter last year. During the same quarter in the previous year, the company posted $0.90 EPS.

Eli Lilly and Company (Lilly) is engaged in drug manufacturing business. The Company discovers develops manufactures and market products in two segments: human pharmaceutical products and animal health products. The Company’s products are sold in approximately 120 countries. The Company’s human pharmaceutical business segment sells medicines which are discovered or developed by its scientists. Its animal health business segment operates through the Company’s Elanco division which develops manufactures and markets products for both food animals and companion animals. The Company manufactures and distributes its products through facilities in the United States Puerto Rico and 11 other countries. Its products include endocrinology products neuroscience products oncology products cardiovascular products products for food animals products for companion animals and Novartis AH products.

Leave a Reply

Eli Lilly and Co - Is it time to Sell?

Top Brokerage Firms are advising their investors on Eli Lilly and Co. Subscribe to MoneyFlowIndex.Org Pre-Market Alerts, You will be the first to know the street buzz.